A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
Abstract Background Glypican-1 is a heparan sulfate proteoglycan that is overexpressed in prostate cancer (PCa), and a variety of solid tumors. Importantly, expression is restricted in normal tissue, making it an ideal tumor targeting antigen. Since there is clinical and preclinical evidence of the...
Main Authors: | Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler, Bradley J. Walsh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-020-07562-1 |
Similar Items
-
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
by: Mei-Chun Yeh, et al.
Published: (2020-05-01) -
Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers
by: Dhanusha Sabanathan, et al.
Published: (2021-07-01) -
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01) -
Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab<sup>®</sup>-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery
by: Dmitry M. Polikarpov, et al.
Published: (2020-04-01) -
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01)